Skip to content

Contact +44 (0) 20 7060 7474 email us

Wyeth

Wyeth

PharmaVitae Profile

Publication Date July 2008
Publisher Datamonitor
Product Type Report
Pages 158
ISBN Number not applicable
Product Code DAT01196

Price

£1,980.00
approximately: $2,998 | €2,210

pdf

Buy Now

print £2,010 ($3,043 | €2,243)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

This analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Wyeth's performance against key rivals in the prescription pharmaceutical sector
  • See how Wyeth's performance to 2013 will be hampered by the demise of four key products, cancelling out growth from a relatively promising pipeline
  • Learn how the company's operating profit growth will be boosted by a strategy of continued cost containment

Contents

  • CHAPTER 1 ABOUT THIS PROFILE
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • CHAPTER 2 EXECUTIVE SUMMARY
    • Key findings
    • Prescription pharmaceutical sales performance, 2001-13
    • Financial performance, 2001-13
    • Wyeth: PharmaVitae forecasts at a glance
    • Strategic insight
    • Five key blockbusters will continue to define performance out to 2013
    • ...masking commercial potential of relatively strong pipeline
    • Falling costs leave the company in a strong financial position
    • SWOT analysis
    • Strengths
    • Strong financial position
    • Enbrel's insulation from generic competition
    • Potential to prolong lifecycle of key products through launch of follow-on products, Prevnar-13 and Pristiq
    • Weaknesses
    • Patent expiry of blockbuster products
    • Opportunities
    • Bapineuzumab potential to break new ground in the Alzheimer's market
    • Use cash reserves to pursue M&A activity or licensing deals
    • Threats
    • Failure to win Protonix court case
    • Failure of late-stage pipeline products to meet their potential
  • CHAPTER 3 QUARTERLY NEWS UPDATE
    • Product developments
    • Deals and alliances
    • Product deals
    • Technology deals
    • M&A activity
    • Company announcements
    • Future product milestones
  • CHAPTER 4 COMPANY INTRODUCTION
    • Key findings
    • Background
    • Key corporate developments
    • M&A history
    • Haptogen
    • Current corporate structure
    • Pharmaceuticals business unit structure
    • Prescription pharmaceuticals
    • Nutritionals
    • Consumer health
    • Animal health
  • CHAPTER 5 COMPANY SALES
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2001-13
    • Product analysis
    • Product analysis, 2001-07
    • Product analysis, 2007-13
    • Therapy area analysis
    • Therapy area analysis, 2001-07
    • Therapy area analysis, 2007-13
    • Therapy area focus, 2001-13
    • Geographic analysis
    • Geographic analysis, 2001-07
    • Geographic analysis, 2007-13
    • Geographic focus, 2001-13
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2007-13
    • Core analysis, 2007-13
    • Expiry analysis, 2007-13
    • Launch/core/expiry configuration, 2007-13
    • Molecule type analysis
    • Molecule type analysis, 2001-07
    • Molecule type analysis, 2007-13
    • Externalization analysis
    • Externalization analysis, 2001-07
    • Externalization analysis, 2007-13
  • CHAPTER 6 COMPANY FINANCIALS
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07
    • Financial statements, 2001-07
    • Profit and loss account, 2001-07
    • Balance sheet, 2001-07
    • Operating costs and profit analysis
    • Operating costs and profit analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2007-13
    • Operating costs and profit analysis, 2007-13
    • Return on capital employed analysis
    • Capital employed analysis, 2001-07
    • Return on capital employed (RoCE) analysis, 2001-07
    • Market capitalization analysis
    • Market capitalization analysis, 2001-07
    • Total shareholder returns analysis, 2001-07
  • CHAPTER 7 KEY PRODUCTS AND COMPETITORS
    • Key findings
    • Overview
    • CNS
    • bapineuzumab
    • Overview
    • Sales forecast
    • Pristiq
    • Overview
    • Sales forecast
    • Product overview
    • Effexor
    • Overview
    • Sales forecast
    • Product overview
    • Infectious diseases
    • Prevnar & Prevnar-13
    • Overview
    • Sales forecast
    • Product overview
    • Tygacil
    • Overview
    • Sales forecast
    • Product overview
    • Tazocin
    • Overview
    • Sales forecast
    • Product overview
    • Inflammation & immunology
    • Enbrel
    • Overview
    • Sales forecast
    • Product overview
    • Urology & gender-specific health disorders
    • Premarin
    • Overview
    • Sales forecast
    • Product overview
    • Gastroenterology
    • Protonix
    • Overview
    • Sales forecast
    • Product overview
    • Musculoskeletal
    • Viviant/Aprela
    • Overview
    • Sales forecast
    • Product overview
  • CHAPTER 8 APPENDIX
    • R&D pipeline
    • References
    • Abbreviations
  • List of Tables
    • Table 1: Wyeth - PharmaVitae forecasts at a glance
    • Table 2: Wyeth key product developments, Q1 2008
    • Table 3: Wyeth product deals and alliances, Q1 2008
    • Table 4: Wyeth technology deals and alliances, Q1 2008
    • Table 5: Wyeth M&A activity, Q1 2008
    • Table 6: Wyeth company announcements, Q1 2008
    • Table 7: Wyeth future product milestones, 2008-10
    • Table 8: Wyeth product portfolio overview ($m), 2001-07
    • Table 9: Wyeth product portfolio overview ($m), 2007-13
    • Table 10: Wyeth product portfolio overview ($m), 2001-07
    • Table 11: Wyeth product portfolio overview ($m), 2007-13
    • Table 12: Wyeth portfolio overview by geographic region ($m), 2001-07
    • Table 13: Wyeth portfolio overview by geographic region ($m), 2007-13
    • Table 14: Wyeth launch portfolio overview ($m), 2007-13
    • Table 15: Wyeth core portfolio overview ($m), 2007-13
    • Table 16: Wyeth expiry portfolio overview ($m), 2007-13
    • Table 17: Wyeth portfolio overview by molecule type ($m), 2001-07
    • Table 18: Wyeth product portfolio overview by molecule type ($m), 2007-13
    • Table 19: Wyeth product portfolio overview by source ($m), 2001-07
    • Table 20: Wyeth product portfolio overview by source ($m), 2007-13
    • Table 21: Total Wyeth sales by business unit ($m), 2001-07
    • Table 22: Wyeth profit and loss account ($m), 2001-07
    • Table 23: Wyeth balance sheet ($m), 2001-07
    • Table 24: Wyeth operating revenue/cost analysis ($m), 2001-07
    • Table 25: Wyeth operating cost ratio analysis (% of total revenues), 2001-07
    • Table 26: Wyeth operating cost ratio analysis (% of total revenues), 2007-13
    • Table 27: Wyeth operating revenue/cost analysis ($m), 2007-13
    • Table 28: Wyeth capital employed ($m), 2001-07
    • Table 29: Wyeth EBIT return on capital employed ($m), 2001-07
    • Table 30: Wyeth EBIT pre-tax return/Capital employed driver analysis (%), 2001-07
    • Table 31: Wyeth market capitalization ($ billion), 2001-07
    • Table 32: Wyeth total shareholder returns (annual %), 2001-07
    • Table 33: Key products overview
    • Table 34: bapineuzumab: overview
    • Table 35: bapineuzumab: sales forecast ($m), 2007-13
    • Table 36: Pristiq: overview
    • Table 37: Pristiq: sales forecast ($m), 2007-13
    • Table 38: Effexor: overview
    • Table 39: Effexor: sales forecast ($m), 2007-13
    • Table 40: Prevnar: overview
    • Table 41: Prevnar-13: overview
    • Table 42: Prevnar: sales forecast ($m), 2007-13
    • Table 43: Prevnar-13: sales forecast ($m), 2007-13
    • Table 44: Tygacil: overview
    • Table 45: Tygacil: sales forecast ($m), 2007-13
    • Table 46: Tazocin: overview
    • Table 47: Tazocin: sales forecast ($m), 2007-13
    • Table 48: Enbrel: overview
    • Table 49: Enbrel: sales forecast ($m), 2007-13
    • Table 50: Premarin: overview
    • Table 51: Premarin: sales forecast ($m), 2007-13
    • Table 52: Protonix: overview
    • Table 53: Protonix: sales forecast ($m), 2007-13
    • Table 54: Viviant/Aprela: overview
    • Table 55: Viviant/Aprela: sales forecast ($m), 2007-13
    • Table 56: Wyeth's R&D pipeline (Phase I-registration)
  • List of Figures
    • Figure 1: Wyeth prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 2: Wyeth's financial performance ($m), 2001-13
    • Figure 3: Blockbusters shape Wyeth's outlook and mask launch performance
    • Figure 4: Reducing S,G&A is key lever on raising operating profit margin
    • Figure 5: Wyeth SWOT analysis
    • Figure 6: Current corporate structure
    • Figure 7: Pharmaceuticals business unit structure
    • Figure 8: Wyeth prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 9: Wyeth key sales growth driver & resistors ($m), 2001-07
    • Figure 10: Wyeth key sales growth drivers & resistors ($m), 2007-13
    • Figure 11: Wyeth prescription pharmaceutical sales by therapy area ($m), 2001-13
    • Figure 12: Wyeth prescription pharma sales by therapy area (% of total), 2001-13
    • Figure 13: Wyeth prescription pharmaceutical sales by geographic region ($m), 2001-13
    • Figure 14: Wyeth growth drivers and resistors by geographic region ($m), 2001-07
    • Figure 15: Wyeth drivers and resistors by geographic region ($m), 2007-13
    • Figure 16: Wyeth prescription pharmaceutical sales by geographic region (% of total), 2001-13
    • Figure 17: Wyeth launch/core/expiry configuration ($m), 2007-13
    • Figure 18: Wyeth prescription pharmaceutical sales by molecule type ($m), 2001-13
    • Figure 19: Wyeth growth drivers and resistors by molecule type ($m), 2007-13
    • Figure 20: Wyeth prescription pharmaceutical sales by source ($m), 2001-13
    • Figure 21: Wyeth growth drivers and resistors by source ($m), 2001-07
    • Figure 22: Wyeth growth drivers and resistors by source ($m), 2007-13
    • Figure 23: Wyeth operating revenue/cost analysis ($m), 2001-13
    • Figure 24: Wyeth operating cost ratio analysis (% of total revenues), 2001-13
    • Figure 25: Wyeth return on capital employed, EBIT margin and capital turnover, 2001-07
    • Figure 26: Return on capital employed formula
    • Figure 27: Wyeth market capitalization ($ billion), 2001-07
    • Figure 28: Wyeth total shareholder returns vs. S&P 500 ($m), 2001-07
    • Figure 29: Prevnar and Prevnar-13 global sales ($m), 2007-13
    • Figure 30: Different scenarios: Protonix